

ASSESSMENT OF SEX HORMONE LEVELS IN HIV SERODISCORDANT COUPLES IN JOS, NIGERIA.

ABSTRACT

This was a cross sectional study design to assess the sex hormone levels in HIV serodiscordant couples in Jos, Nigeria. A total of 20 discordant HIV couples (40 patients) and 20 controls (40 non HIV couples) aged between 18 and 49 years were included in the study. 5ml of fasting venous blood sample was collected from each participant into plain containers for the evaluation of sex hormones levels. Female samples were taken two weeks prior to menstruation (follicular phase). Follicle stimulating hormone (FSH), luteinizing hormone (LH), progesterone, estrogen/estradiol (E_2), and testosterone (TT) were determined by using standard ELISA technique. The results revealed that while there was no statistically significant difference in the mean serum levels of LH, Testosterone, progesterone, or estradiol between the HIV serodiscordant couples and the control group ($p>0.05$), FSH level in the HIV serodiscordant couples was significantly lower than in the control group (7.84 ± 7.39 Vs 10.62 ± 4.19 ; $p=0.042$). However, gender comparison showed that FSH, LH and progesterone levels in the male and female HIV discordant groups were not significantly different from those in the male and female control groups, respectively ($p>0.05$). TT level was significantly lower while E_2 was higher in the male HIV discordant group than in the male control group ($p=0.000$) whereas E_2 level was significantly lower in the female HIV discordant group than in the female control group ($p=0.000$). Furthermore, the mean serum TT levels was significantly lower in the male exposed HIV seronegative individuals compared to male control ($p=0.000$) while progesterone level was significantly lower in the male HIV seropositives than in the male control ($p=0.021$) as well as in the male exposed HIV seronegative individuals compared to the male HIV seropositive individuals ($p=0.000$). This study revealed significant alterations in the sex hormone levels in HIVserodiscordant couples and this requires further studies with larger sample size to ascertain the current findings.

KEY WORDS: HIV, HIV Serodiscordant couple, Sex hormones, Gender.

INTRODUCTION

Since the AIDS epidemic began, 36.3 million people have died from AIDS, making the Human Immunodeficiency Virus (HIV) a global public health issue that affects humankind (World Health Organisation (WHO), 2021), and most recently, 37.7 million people were infected by HIV in the year 2020 (UNAIDS, 2022). It affects 71% of people worldwide and is the main cause of morbidity and mortality in Sub-Saharan Africa (James *et al.*, 2018). Nigeria, the most

populated nation in Africa (UNFPA, 2020), has the third-highest HIV load with 1.9 million persons living with the virus (with a prevalence of 1.4 percent) between the ages of 15 and 49 (UNAIDS, 2019). HIV results in a decreased immune response marked by CD4-T cell depletion, which renders the host vulnerable to a variety of infections and illnesses (Ezeugwunne *et al.*, 2021; Ogbodo *et al.*, 2021, Ezeugwunne *et al.*, 2021) and may be responsible for changes in a number of biomarkers seen in HIV-infected people.

For a healthy reproductive system, it is crucial to have adequate levels of reproductive hormones such as FSH, LH, testosterone, estrogen, and progesterone. Nevertheless, studies have shown significant alterations in these hormones which may undermine the reproductive function in these individuals (Ezeugwunne *et al.*, 2019). HIV is known to have an adverse effect on women's reproductive health (Kumari *et al.*, 2016; Ikechebelu *et al.*, 2002; Fallahian and Ilkhani, 2006). Menstrual irregularities to complete infertility are among the detrimental effects on reproduction (Yalamanchi *et al.*, 2014). Some of these conditions could come from abnormal ovarian function, which would have a significant impact on sex hormones (Yalamanchi *et al.*, 2014). It cannot be overemphasized that antiretroviral therapy (ART) improves sex hormone and gonadal function in HIV-positive subjects; yet, controversial studies have indicated that antiretroviral therapy's long-term use can have a negative impact on sex hormones in infected individuals (Hutchinson *et al.*, 2000). Reduced ovarian function is another factor contributing to the significantly lower testosterone levels in HIV-positive female ART subjects compared to Control females. In the course of normal physiology, the ovaries of females produce very small amounts of testosterone that are used to maintain muscle mass and thus prevent weight loss (Ukibe *et al.*, 2015). There is diverse evidence of hypogonadism in HIV-positive persons (Aggarwal *et al.*,

2018). Additionally, it has been found that the prevalence of hypogonadism is highly connected with the severity of immunodeficiency, increasing as CD4 levels fall. (Aggarwal *et al.*, 2018).

Since those who are HIV exposed but seronegative and involved in these relationships are at risk for contracting the virus, which could predispose them to the significant alterations in sex hormone levels, hormonal dysregulation is a crucial issue to take into account for HIV serodiscordant couples with the goal of having children. Furthermore, early clinical testicular dysfunction and hypogonadism diagnosis and appropriate treatment may improve clinical outcomes and quality of life for those who are affected. Therefore, it is necessary to measure the levels of sex hormones in the HIV serodiscordant couples in Jos, Nigeria.

MATERIALS AND METHODS

Study Area and Location

The study area for this work was Jos North Local Government Area of Plateau State and location includes APIN (Aids Preventive Initiative of Nigeria) section of Our Lady of Apostles (OLA) Hospital, Faith Alive Foundation Hospital and Plateau State Specialist Hospital where HIV screenings are carried out.

Study Design and Subject Selection

An approach known as a cross sectional research was used for this experiment. The participants were partners who were known to be HIV positive and exposed seronegatives and are between the ages of 18 and 49 years old. In addition, controls consisting of HIV-negative couples in the aforementioned age group who appeared to be in healthy condition were used. The HIV-positive

individuals were already taking antiretroviral drugs, but the negative individuals in the discordant relationship were not.

Study Population

The present research included male and female participants in serodiscordant relationship within the age of 18 to 49 years attending the APIN section of Our Lady of Apostles Hospital, Faith Alive Foundation and Plateau State Specialist Hospital. A total of 20 discordant HIV couples (40 patients) and 20 controls (40 non HIV couples) were included in the study.

Sample Collection

Following sterilizing the collection site with 70% alcohol, five milliliters of venous blood were drawn into plain containers, allowed to clot, and then retracted while serum was recovered after centrifugation at 3,000 rpm for five minutes. Unanalyzed serum samples were kept frozen at -20°C for later analysis. All blood samples were taken while fasting, and female samples were taken two weeks prior to menstruation (follicular phase).

Inclusion criteria

HIV-negative individuals who had been in a committed, discordant relationship for at least three months were eligible to participate. Participants in the study were between the ages of 18 and 49, registered patients at the hospital under study, and have the required status documentation. A control group of participants in the same age range who seemed healthy was also included in the study (non HIV subjects).

Exclusion Criteria

Participants who were already bedridden due to AIDS, diabetics, contraceptive users, those who were not registered patients or had improper documentation with the institution under research, and those who refused to give informed consent were all excluded from the study.

Laboratory methods

Using the Enzyme Linked Immunosorbent Assay (ELISA) technique, the sex hormones FSH, LH, Testosterone, Estrogen/Estradiol, and Progesterone were assayed.

Statistical Analysis

Using the SPSS statistics tool version 23.0 software, the data were examined using independent t-test and one-way analysis of variance (ANOVA). A significant level of $p < 0.05$ was assumed.

RESULTS

When compared to the control group, the HIV serodiscordant couples had significantly lower mean serum FSH levels (7.84 ± 7.39 Vs 10.62 ± 4.19 ; $p = 0.042$), while there was no statistically significant difference in the mean serum LH ($p = 0.756$), Testosterone ($p = 0.567$), progesterone ($p = 0.248$) and estradiol ($p = 0.319$) levels in the HIV serodiscordant couples when compared to the control group. See table 1.

Furthermore, gender comparison showed that FSH, LH and progesterone levels in the male and female HIV discordant groups were not significantly different ($p > 0.05$) from those in the male and female control groups, respectively (Table 2). There was significantly lower mean serum testosterone and higher E_2 levels in the male HIV discordant group when compared to the male control ($p = 0.000$). Also, there was significantly higher mean serum testosterone level in the male HIV discordant group than in the female control group and female HIV discordant group

($p=0.000$). Additionally, the mean serum testosterone level in the male control group was significantly higher than that in the female control group ($p=0.000$). See table 2.

Although the mean serum progesterone levels were significantly lower in the male HIV discordant group when compared to the female control group ($p=0.021$), the difference between the mean serum progesterone levels in the male and female HIV discordant group compared to their respective control groups was not statistically significant ($p>0.05$). See table 2.

In the female HIV discordant group compared to the female control group, the mean serum estradiol level was similarly significantly lower ($p=0.000$), but in the male HIV discordant group compared to the male control group, there was no significant difference ($p>0.05$). See table 2.

When examined across and between the groups, respectively, the mean serum FSH and LH levels in the study groups did not differ significantly ($p>0.05$). When compared to male controls, the mean serum testosterone level among male HIV seropositives did not differ significantly ($p>0.05$). Male HIV seronegative exposed individuals had mean serum testosterone levels that were significantly lower than those of the male controls ($p=0.000$).

The mean serum testosterone level was significantly higher in the male control than in the female control ($p=0.000$). The mean serum testosterone level was significantly lower in the female seropositives and female exposed HIV seronegatives than in the male control ($p=0.000$). See table 3.

The mean serum progesterone level was significantly different compared amongst the groups ($F=3.425$, $p=0.02$). The mean serum progesterone level was significantly lower in male HIV seropositives compared to female control; male control, female HIV positive and female HIV

negative respectively ($p=0.021$). The mean serum progesterone level was significantly lower in male exposed HIV seronegatives when compared to female HIV positive ($p=0.021$). See table 3.

The mean serum estradiol level in the male control was significantly lower compared to the female control ($p=0.000$) while the mean serum estradiol level in the female HIV seropositives was significantly higher compared to the male control ($p=0.000$). Also, the mean serum estradiol level in the female HIV exposed seronegatives was significantly higher compared to the male control ($p=0.000$) whereas there was significantly lower estradiol levels in the male HIV positive individuals when compared to the female control, female HIV seropositive and female exposed HIV seronegative individuals respectively ($p=0.000$). Furthermore, there was significantly lower estradiol levels in the male HIV exposed seronegative individuals when compared to the female control, female HIV seropositive and female exposed HIV seronegative individuals respectively ($p<0.05$). See table 3.

Table 1: Serum FSH, LH, Testosterone, progesterone and Estradiol Levels in the HIV Serodiscordant couples (mean \pm SD)

Parameter	Control (n=40)	HIV serodiscordant couples (n=40)	t-value	p-value
FSH (IU/mL)	10.62 \pm 4.19	7.84 \pm 7.39	2.073	0.042*

LH(IU/mL)	8.07±1.33	7.79±3.51	0.313	0.756
Testosterone(ng/mL)	4.30±2.68	3.86±1.07	0.575	0.567
Progesterone(ng/mL)	0.46±0.13	0.36±0.18	1.164	0.248
Estradiol(ng/mL)	83.70±15.73	65.66±14.75	1.004	0.319

*Statistically significant at p<0.05.

Table 2: Gender comparison of serum FSH, LH, Testosterone, progesterone and Estradiol Levels in the HIV Serodiscordant couples (mean±SD)

Parameter	Female control	Male control	Female HIV discordant	Male HIV discordant	f-value	p-value
-----------	----------------	--------------	-----------------------	---------------------	---------	---------

	(n=20)	(n=20)	group (n=20)	group (n=20)		
FSH(IU/mL)	9.87±1.08	11.37±5.80	7.00±2.29	8.67±2.27	1.883	0.140
LH(IU/mL)	8.89±1.29	7.25±0.75	7.20±2.10	8.38±1.56	0.886	0.452
Testosterone(ng/mL)	0.71±0.12	7.88±0.81	1.77±0.87 ^b	5.95±1.41 ^{a,b,c}	84.86	0.000
L)		a			5	*
Progesterone(ng/mL)	0.60±0.17	0.33±0.11	0.48±0.16	0.23±0.14 ^a	3.425	0.021
L)						*
Estradiol (ng/mL)	158.15±10.19	9.26±0.37	109.30±14.51 ^a	22.03±4.46 ^{a,b}	37.43	0.000
		a	,b	,c	9	*

*Statistically significant at p<0.05.

Key:

a=compared with female control

b= compared with male control

c= compared with female HIV positive

Table3: Hormone profile levels in the participant groups studied (mean±SD)

Parameter	Female control (n=20)	male control (n=20)	Female positives (n=16)	Female negatives (n=4)	male positives (n=16)	male negatives (n=4)	f-value	p-value
FSH(IU/mL)	9.87±1.08	11.37±5.80	7.06±2.49	6.75±1.42	4.88±0.92	9.62±1.34	1.527	0.192
LH(IU/mL)	8.89±1.29	7.25±0.75	7.70±1.77	5.18±2.34	5.30±0.89	9.15±2.31	1.426	0.225
Testosterone (ng/mL)	0.71±0.12	7.88±0.81 ^a	2.11±1.13 ^b	0.43±0.05 ^b	5.28±0.86 ^{a,c,d}	6.12±1.49 ^{a,b,c,d}	53.309	0.000*
Progesterone (ng/mL)	0.60±0.17	0.33±0.13	0.46±0.16	0.56±0.11	0.23±0.14 ^{a,b,c,d}	0.21±0.13 ^c	3.425	0.021*
Estradiol (ng/mL)	158.15±10.19	9.26±0.37 ^a	106.03±10.10 ^b	122.38±1.18 ^b	3.88±0.78 ^{a,c,d}	26.57±6.62 ^{a,c,d}	22.323	0.000*

Key:

a=compared with female control

b= compared with male control

c= compared with female HIV positive

d= compared with female HIV negative

e= compared with male HIV positive

DISCUSSION

Currently, there is a lot of discussion about the human immunodeficiency virus (HIV), with more complex issues regarding HIV serodiscordant couples emerging. Given the foregoing, the current study examined the levels of sex hormones in the serodiscordant couples in Jos, Nigeria.

In this study, there was no statistically significant difference in the mean serum levels of LH, Testosterone, progesterone, or estradiol between the HIV serodiscordant couples and the control group respectively. However, FSH level in the HIV serodiscordant couples was significantly lower than in the control group. The limited sample size used in the current investigation may have had an impact on these results. Furthermore, given that those who were HIV positive were already getting antiretroviral therapy, starting that treatment may have helped these people have improved levels of these hormones. Antiretroviral therapy has been shown to improve sexual functions in human immunodeficiency virus infected individuals (Yelwa *et al.*, 2020). In contrast to the present study, several other studies in HIV infected individuals reported significantly lower testosterone with increased FSH, LH and E₂ levels compared to control subjects (Yelwa *et al.*, 2020; Ezeugwunne *et al.*, 2019).

The mean serum testosterone level in the male HIV discordant group was significantly lower than that in the male control group while the mean serum estradiol level in the male HIV discordant group was significantly higher than that in the male control group. However, when compared between the male HIV discordant groups and the male control groups, the mean serum FSH, LH, and progesterone levels did not differ significantly. This finding is partly consistent with previous studies (Ezeugwunne *et al.*, 2012). This suggests that the HIV infection may have

encouraged the production of estrogen from testosterone, a process known as the estrogenic effect, which is the cause of the low levels of serum testosterone found in these people.

Testosterone is peripherally converted to estrogen by the enzymes aromatase and enolase to produce the estrogenic action. Furthermore, some previous investigations found that the serum levels of the reproductive hormones in HIV seropositive males receiving antiretroviral therapy (ART) and those not receiving ART both significantly decreased when compared to HIV seronegative male control participants (Oluboyo *et al.*, 2014) which they attributed to the disturbances in hypothalamic-pituitary-gonadal axis or due to metabolic abnormalities associated with HIV/AIDS and this is partly in keeping with the present results.

In this study, when the female HIV serodiscordant group and the female control group were compared, the mean serum levels of testosterone, FSH, LH, and progesterone did not differ significantly while in the female HIV discordant group, the mean serum estradiol level was significantly lower than in the female control group. This is in keeping with the results of some previous studies (Yalamanchi *et al.*, 2014). Oluboyo and colleagues had earlier reported no significant differences in the mean serum fertility hormone levels in the HIV infected females than in the control subjects (Oluboyo *et al.*, 2014). Furthermore, Ukibe *et al.* had shown that Progesterone, estradiol, and testosterone levels were significantly lower in HIV-infected women than in controls during the follicular and luteal phases of the menstrual cycle, indicating some degree of hypogonadism in these women that may have some bearing on their ability to reproduce.

The mean serum FSH and LH levels in the study groups did not differ significantly when compared within or across groups. When compared to male controls, the mean serum testosterone level among male HIV seropositives did not differ significantly. The mean serum

progesterone level was significantly lower in male HIV seropositives compared to the male control. Also, the male HIV seronegative exposed individuals had mean serum testosterone levels that were significantly lower than those of the male controls. This may imply that male HIV-exposed seronegative partners in discordant relationships may eventually develop hypogonadism if untreated.

CONCLUSION

This study revealed significant alterations in the sex hormone levels in HIV-discordant couples, which is crucial for the desire to boost fertility through early detection and subsequent intervention in these individuals. This requires further studies with larger sample size to ascertain the current findings.

Ethical Approval

The facilities where the study was conducted—Our Lady of Apostles Hospital (dated 13th June, 2018), Faith Alive Foundation Hospital (FAFEC/08/34/25) and Plateau State Specialist Hospital (PSSH/ADM/ETH.CO/2019/005)—all granted ethical approval for the study.

Consent

As per international standard or university standard, patients' written consent has been collected and preserved by the author(s).

References

Aggarwal J, Taneja RS, Gupta PK, Wali M, Chitkara A, Jamal A. Sex hormone Profile in Human Immunodeficiency Virus-Infected Men and It's Correlation with CD4 Cell Counts. Indian J Endocrinol Metab. 2018; 22(3):328-34.

Ezeugwunne IP, Ogbodo EC, Analike RA, Ob-Ezeani CN, Onuora IJ, Oguaka VN, et al. Serum Reproductive hormone levels in male symptomatic HIV/AIDS patients on Antiretroviral therapy

negative to Malaria parasite in Nnewi, Anambra State, Nigeria. *Asian J Med Sci.* 2019; 10(3):44-9.

Ezeugwunne IP, Ogbodo EC, Analike RA, Okwara NA, Nnamdi JC, Iwuji JC, et al. The pattern of alpha-fetoprotein, CD4+ count, albumin, AST, ALT and ALP in HIV subjects on long term antiretroviral therapy in Nnewi, Anambra State, Nigeria. *Indian J Forensic Community Med.* 2021; 8(1):45-51.

Ezeugwunne IP, Ogbodo EC, Ezeuduji OO, Iwuji JC, Okwara NA, Obi-Ezeani CN, et al. Assessment of Alpha-Fetoprotein, Albumin, Cd4+ and Some Liver Enzymes in HIV Infected Adult on Art in Nnewi, South Eastern Nigeria. *Advan Biores.* 2021; 12(4):199-205.

Ezeugwunne IP, Onyenekwe CC, Ahaneku JE, Ifeanyichukwu M, Meludu SC, Onwurah OW, et al. Serum hormonal levels in HIV/AIDS infected male subjects on antiretroviral therapy (ART) in Nnewi, Nigeria. *Int J Biol Chem Sci.* 2012; 6(4): 1409-18.

Fallahian M, Iikhani M. Menstrual Disorders in Nongenital Tuberculosis. *Infect Dis Obstet Gynecol.* 2006; 18452:1-3.

Hutchinson J, Murphy M, Harries R, Skinner CJ. Galactorrhoea and hyperprolactinaemia associated with protease inhibitors. *Lancet* 2000; 356:1003-1004.

Ikechebelu JI, Ikegwuonu SC, Joe-Ikechebelu NN. HIV Infection and Sexual behaviours among infertile women in Southwestern, Nigeria. *J Obstet Gynaecol.* 2002; 22(3): 306-307.

James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018; 392(10159):1789-1858.

Kumari A, Seth S, Chaudhary U, Ghalaut VS, Bansal P, Kulshreshtha MR. Emerging reproductive hormones perturbations in hiv positive females: a north indian study. *Int J Adv Res.* 2016; 4(9), 68-73.

Ogbodo EC, Ezeugwunne IP, Ezeuduji OO, Analike RA, Okezie OA, Onuora IJ, et al. Gender Comparison Of Alpha-Fetoprotein, CD4, Albumin and Some Liver Enzymes in Symptomatic HIV Subjects on Antiretroviral Therapy. *J Progressive Res Biol.* 2021; 5(1):17-25.

Oluboyo AO, Ihejmkpo AE, Onyenekwe CC, Oluboyo BO, Amah UK, Okwara JE, et al.

Fertility Hormones, CD4+T Cells and CD8+Tcells In HIV Seropositive Subjects In Onitsha, Nigeria. *Arch Bas App Med.* 2014; 2:35 -8

Ukibe NR, Ukibe SN, Emelumadu FO, Ifeadike OC, Onyenekwe CC, Ahaneku JE, Ilika LA. cytokines changes associated with menstrual cycle in hiv infected females at NAUTH, Nnewi, South-east Nigeria. Euro Sci J. 2015; 11(18):134-142.

UNAIDS (2019). Press Release

[https://www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2019/march/20190314_nigeria]. (Retrieved July 10, 2022).

UNAIDS. (2022). Global HIV and AIDS statistics — Fact sheet. Retrieved from:

<https://www.unaids.org/en/resources/fact-sheet> (Retrieved July 10, 2022).

UNFPA. (2020). World population dashboard Nigera, 2020.

https://scholar.google.com/scholar_lookup?title=World%20population%20dashboard%20Nigera&publication_year=2020 (Retrieved July 10, 2022).

WHO (2021). HIV/AIDS fact sheet. Retrieved: <https://www.who.int/news-room/fact-sheets/detail/hiv-aids> (Retrieved July 10, 2022).

Yalamanchi S, Dobs A, Greenblatt RM. Gonadal function and reproductive health in women with HIV infection. Endocrinol Metab Clin North Am. 2014; 43(3): 731–41.

Yelwa AA, Mainasara AS, Akuyam SA, Adamu BI, Umar ZU, Abubakar SD, et al. Evaluation of serum sex hormones and CD4+ count among HIV patients on HAART, HAART naive patients and apparently healthy subjects in Sokoto, Nigeria. Int J Res Med Sci 2020;8:891-5.

UNDER PEER REVIEW